Trial Profile
A study of the efficacy and safety of CMA-676 [gemtuzumab ozogamicin] as single agent treatment of patients with acute myeloid leukemia (AML) in first relapse
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Gemtuzumab ozogamicin (Primary)
- Indications Acute myeloid leukaemia
- Focus Registrational; Therapeutic Use
- Sponsors Wyeth
- 29 Sep 2005 New trial record.